JP2024526334A5 - - Google Patents
Info
- Publication number
- JP2024526334A5 JP2024526334A5 JP2024501787A JP2024501787A JP2024526334A5 JP 2024526334 A5 JP2024526334 A5 JP 2024526334A5 JP 2024501787 A JP2024501787 A JP 2024501787A JP 2024501787 A JP2024501787 A JP 2024501787A JP 2024526334 A5 JP2024526334 A5 JP 2024526334A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- lvot
- pharmaceutically acceptable
- acceptable salt
- lvef
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203333P | 2021-07-16 | 2021-07-16 | |
| US63/203,333 | 2021-07-16 | ||
| US202263299753P | 2022-01-14 | 2022-01-14 | |
| US63/299,753 | 2022-01-14 | ||
| US202263305609P | 2022-02-01 | 2022-02-01 | |
| US63/305,609 | 2022-02-01 | ||
| US202263331197P | 2022-04-14 | 2022-04-14 | |
| US63/331,197 | 2022-04-14 | ||
| US202263343975P | 2022-05-19 | 2022-05-19 | |
| US63/343,975 | 2022-05-19 | ||
| PCT/US2022/073808 WO2023288324A1 (en) | 2021-07-16 | 2022-07-15 | Methods for treating hypertrophic cardiomyopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024526334A JP2024526334A (ja) | 2024-07-17 |
| JP2024526334A5 true JP2024526334A5 (https=) | 2025-07-23 |
Family
ID=82850823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024501787A Pending JP2024526334A (ja) | 2021-07-16 | 2022-07-15 | 肥大型心筋症を治療するための方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20230058927A1 (https=) |
| EP (2) | EP4548912A3 (https=) |
| JP (1) | JP2024526334A (https=) |
| KR (1) | KR20240047359A (https=) |
| AU (1) | AU2022312506A1 (https=) |
| CA (1) | CA3225787A1 (https=) |
| CL (2) | CL2024000090A1 (https=) |
| DK (1) | DK4370116T3 (https=) |
| ES (1) | ES3014965T3 (https=) |
| FI (1) | FI4370116T3 (https=) |
| HR (1) | HRP20250174T1 (https=) |
| HU (1) | HUE070699T2 (https=) |
| IL (1) | IL310140A (https=) |
| LT (1) | LT4370116T (https=) |
| MX (1) | MX2024000804A (https=) |
| PL (1) | PL4370116T3 (https=) |
| PT (1) | PT4370116T (https=) |
| RS (1) | RS66640B1 (https=) |
| SI (1) | SI4370116T1 (https=) |
| SM (1) | SMT202500098T1 (https=) |
| TW (1) | TW202320763A (https=) |
| WO (1) | WO2023288324A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| EP4565230A1 (en) * | 2022-08-04 | 2025-06-11 | Cytokinetics, Inc. | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024182469A1 (en) * | 2023-02-28 | 2024-09-06 | MyoKardia, Inc. | Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy |
| WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| US20250295639A1 (en) | 2024-03-20 | 2025-09-25 | Cytokinetics, Incorporated | Methods for treating heart diseases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060292695A1 (en) * | 2005-06-22 | 2006-12-28 | Roslin Institute | Methods and kits for drug screening and toxicity testing using promoter-reporter cells derived from embryonic stem cells |
| CA3071948A1 (en) * | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| WO2020257609A1 (en) | 2019-06-21 | 2020-12-24 | MyoKardia, Inc. | Diagnostics and treatments for cardiac disease |
| RS65302B1 (sr) | 2019-07-17 | 2024-04-30 | Cytokinetics Inc | Oralne formulacije inhibitora srčanog sarkomera |
| EP3999180B1 (en) | 2019-07-17 | 2024-05-08 | Cytokinetics, Inc. | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
| EP4054588A4 (en) | 2019-11-10 | 2023-12-13 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| MX2023002024A (es) | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| CN114456163B (zh) | 2020-11-09 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114516843B (zh) | 2020-11-19 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| WO2022105852A1 (zh) | 2020-11-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114539257B (zh) | 2020-11-24 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用 |
| CN114539229B (zh) | 2020-11-24 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN116507621B (zh) | 2020-11-24 | 2025-10-17 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| MX2024001294A (es) | 2021-08-03 | 2024-02-13 | Cytokinetics Inc | Proceso para la preparacion de aficamten. |
| EP4514355A1 (en) | 2022-04-26 | 2025-03-05 | MyoKardia, Inc. | Methods of administering myosin inhibitors |
| WO2024020468A1 (en) | 2022-07-20 | 2024-01-25 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| EP4565230A1 (en) | 2022-08-04 | 2025-06-11 | Cytokinetics, Inc. | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024050139A1 (en) | 2022-09-02 | 2024-03-07 | AnaBios Corporation | Therapeutic uses of cardiac myosin inhibitors |
| CN120187352A (zh) | 2022-10-21 | 2025-06-20 | 普若莱奥公司 | 治疗肥厚型心肌病的系统和方法 |
| WO2024097284A1 (en) | 2022-11-02 | 2024-05-10 | MyoKardia, Inc. | Mavacamten and derivatives thereof for use in treating atrial dysfunction |
| WO2024134498A1 (en) | 2022-12-22 | 2024-06-27 | Assia Chemical Industries Ltd. | Solid state forms of aficamten and process for preparation thereof |
| WO2024173765A1 (en) | 2023-02-17 | 2024-08-22 | Bristol Myers Squibb Company | Methods of prognosis and treatment for heart failure with preserved ejection fraction using urinary protein levels |
| WO2024182469A1 (en) | 2023-02-28 | 2024-09-06 | MyoKardia, Inc. | Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy |
| WO2024179422A1 (zh) | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| WO2025096779A2 (en) | 2023-11-01 | 2025-05-08 | Bristol Myers Squibb Company | Methods of treatment with a myosin inhibitor using protein levels |
-
2022
- 2022-07-15 PT PT227539533T patent/PT4370116T/pt unknown
- 2022-07-15 LT LTEPPCT/US2022/073808T patent/LT4370116T/lt unknown
- 2022-07-15 FI FIEP22753953.3T patent/FI4370116T3/fi active
- 2022-07-15 EP EP25151678.7A patent/EP4548912A3/en active Pending
- 2022-07-15 AU AU2022312506A patent/AU2022312506A1/en active Pending
- 2022-07-15 HR HRP20250174TT patent/HRP20250174T1/hr unknown
- 2022-07-15 PL PL22753953.3T patent/PL4370116T3/pl unknown
- 2022-07-15 MX MX2024000804A patent/MX2024000804A/es unknown
- 2022-07-15 IL IL310140A patent/IL310140A/en unknown
- 2022-07-15 CA CA3225787A patent/CA3225787A1/en active Pending
- 2022-07-15 WO PCT/US2022/073808 patent/WO2023288324A1/en not_active Ceased
- 2022-07-15 JP JP2024501787A patent/JP2024526334A/ja active Pending
- 2022-07-15 HU HUE22753953A patent/HUE070699T2/hu unknown
- 2022-07-15 DK DK22753953.3T patent/DK4370116T3/da active
- 2022-07-15 SM SM20250098T patent/SMT202500098T1/it unknown
- 2022-07-15 KR KR1020247002855A patent/KR20240047359A/ko active Pending
- 2022-07-15 SI SI202230095T patent/SI4370116T1/sl unknown
- 2022-07-15 US US17/812,994 patent/US20230058927A1/en not_active Abandoned
- 2022-07-15 EP EP22753953.3A patent/EP4370116B1/en active Active
- 2022-07-15 TW TW111126631A patent/TW202320763A/zh unknown
- 2022-07-15 ES ES22753953T patent/ES3014965T3/es active Active
- 2022-07-15 RS RS20250239A patent/RS66640B1/sr unknown
-
2024
- 2024-01-10 CL CL2024000090A patent/CL2024000090A1/es unknown
- 2024-06-25 CL CL2024001945A patent/CL2024001945A1/es unknown
- 2024-10-08 US US18/909,401 patent/US12370179B1/en active Active
- 2024-10-15 US US18/916,215 patent/US20250177357A1/en active Pending
-
2025
- 2025-07-01 US US19/257,352 patent/US20260097021A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024526334A5 (https=) | ||
| JP2023501453A5 (https=) | ||
| JP2020529996A5 (https=) | ||
| KR20240047359A (ko) | 비대성 심근병증을 치료하는 방법 | |
| Arrighi et al. | Improvement of the age-related impairment in left ventricular diastolic filling with verapamil in the normal human heart. | |
| JP2025515491A5 (https=) | ||
| CN109069589A (zh) | 用于心血管病况的司美鲁肽 | |
| JP2020536121A (ja) | 駆出率が保持された心不全を治療する方法 | |
| JP2013528649A (ja) | 肺高血圧症の処置のために使用するためのラノラジン | |
| Okajima et al. | Assessment of pulmonary hypertension: what CT and MRI can provide | |
| Nguyen et al. | Pericarditis related to post-acute COVID infection: A case report and review of the literature | |
| Soma et al. | Regular treatment strategy with a large amount of carvedilol for heart failure improves biventricular systolic failure in a patient with repaired tetralogy of Fallot | |
| JP2025513337A5 (https=) | ||
| Shikama et al. | Assessment of myocardial perfusion and fatty acid metabolism in a patient with Churg-Strauss syndrome associated with eosinophilic heart disease | |
| RU2024101409A (ru) | Способы лечения гипертрофической кардиомиопатии | |
| Shimakura et al. | Improvement of cardiac function after treatment with octreotide followed by trans-sphenoidal surgery in an acromegalic patient who presented with congestive heart failure | |
| Shimozono et al. | Effectiveness and safety of tolvaptan in patients with aortic stenosis | |
| Jaworska-Wilczyńska et al. | Post-cardiac injury syndrome | |
| Wan et al. | Case Report of Loffler endocarditis diagnosis made with contrast-enhanced echocardiography | |
| HK40105016A (zh) | 用於治疗肥厚型心肌病的方法 | |
| Caccitolo et al. | Operation for anorexigen-associated valvular heart disease | |
| Desantis et al. | ROLE OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND CORRELATION WITH VASCULAR STIFFNESS AND ORGAN DAMAGE | |
| Shi et al. | A Rare Case of Postcardiac Injury Syndrome Caused by Radiofrequency Catheter Ablation of Persistent Atrial Fibrillation: Severe Pulmonary Arterial Hypertension with Severe Tricuspid Regurgitation | |
| Jena et al. | Surgical Aortic Valve Replacement to Treat Prosthetic Valve Endocarditis After Valve-in-Valve Transcatheter Aortic Valve Replacement | |
| Del Punta et al. | BIO-HUMORAL AND HAEMODYNAMIC CORRELATES OF RENAL VENOUS CONGESTION IN THE HEART FAILURE SPECTRUM |